Peptides for Skin and Aesthetics: Beyond GHK-Cu

For most aesthetic practices, GHK-Cu is the first peptide they meet and often the only one they can describe with any confidence. That is a reasonable place to start, because GHK-Cu is the most-studied skin peptide in the published literature and one of the few where the marketing and the research sit close together.¹ But providers who are evaluating a peptide line quickly discover the category is larger than one molecule, and that the peptides marketed for skin do very different things through very different mechanisms. This article maps the aesthetic peptide landscape beyond GHK-Cu and, more usefully, grades what the human evidence actually supports for each family. It is written for providers, and it describes mechanisms and research rather than promising outcomes.

Three Families of "Skin Peptide" (and Why the Distinction Matters)

The single most useful thing a provider can understand about aesthetic peptides is that the word "peptide" on a label tells you almost nothing about what the product does. Three distinct families get sold under the same term, and they are not interchangeable. We covered the underlying naming problem in our piece on collagen versus signal peptides; here is how it plays out across the aesthetic category.

Signal peptides, or matrikines, are short fragments that act as messengers to dermal fibroblasts, nudging them to produce more collagen and extracellular matrix. The best-known is palmitoyl pentapeptide, pal-KTTKS, marketed as Matrixyl. It was designed specifically as a topical agent to stimulate collagen production for an anti-wrinkle benefit, and a controlled study reported measurable improvement in the appearance of photoaged human facial skin compared with placebo.² These peptides work topically and locally.

Neurotransmitter-modulating peptides take a completely different approach: instead of building matrix, they aim to relax the micro-contractions that fold skin into expression lines. Acetyl hexapeptide, known by the trade name Argireline (originally acetyl hexapeptide-3, now commonly labeled acetyl hexapeptide-8), was rationally designed to inhibit neurotransmitter release in a manner that loosely emulates botulinum toxin, at far lower efficacy. In its original study, a 10 percent emulsion reduced measured wrinkle depth by up to 30 percent over 30 days of treatment, and the authors framed it as a biosafe topical alternative rather than a substitute for injectables.³

Structural, or collagen, peptides are the ingestible family. These are hydrolyzed collagen, broken into di- and tripeptides small enough to be absorbed and to circulate. They are not signaling molecules in the matrikine sense; they supply amino-acid building blocks and appear to prompt a systemic collagen-synthesis response. Critically for this site, this is the one aesthetic peptide family whose evidence is built on oral, human, placebo-controlled trials.

What the Human Evidence Actually Supports

Grading these families honestly matters, because their evidence quality is not equal, and a provider who treats them as equivalent will overclaim on the weakest ones.

The oral collagen peptides have the strongest human evidence of the three. A double-blind, placebo-controlled study of specific collagen peptides reported a statistically significant improvement in skin elasticity over an eight-week treatment period in women aged 35 to 55.⁴ A separate randomized, placebo-controlled trial in 72 women aged 35 and older found improvements in skin hydration, elasticity, roughness, and density over twelve weeks, measured with objective instruments rather than self-report.⁵ And a 2021 systematic review and meta-analysis pooling 19 randomized controlled trials with 1,125 participants concluded that hydrolyzed collagen supplementation over roughly 90 days was associated with reduced wrinkling and improved elasticity and hydration.⁶ This is a genuinely rare situation in the peptide world: multiple RCTs and a meta-analysis pointing the same direction.

The topical signal peptides and neuromodulating peptides sit a rung lower. The pal-KTTKS and Argireline studies are real and peer-reviewed, but they are smaller, use cosmetic endpoints such as skin topography and wrinkle depth, and several were conducted in the cosmetic-development context. That does not make them worthless; it means the honest description is "improves the appearance of" rather than "reverses" or "treats," and that the effect sizes are modest. A provider can present these peptides accurately without implying a clinical outcome, and doing so is what keeps the conversation credible with a skeptical audience.

Where GHK-Cu Still Sits in the Landscape

None of this displaces GHK-Cu; it contextualizes it. GHK-Cu is a naturally occurring copper-binding tripeptide with documented activity across collagen synthesis, antioxidant pathways, and tissue remodeling, and the review literature treats it as one of the most broadly characterized skin peptides available.¹ Its breadth of mechanism, its endogenous origin, and the depth of its literature are exactly why it remains the most defensible first peptide for an aesthetic practice to stock. The families above are best understood as the layers a practice can add once GHK-Cu is established, not as replacements for it. Our companion reference on GHK-Cu and skin rejuvenation covers that starting point in detail.

The Oral Delivery Angle

The evidence review above quietly makes a point that matters for an oral-strip program: at least one aesthetic peptide family, hydrolyzed collagen, already has its human efficacy data on the oral route. Ingestion is not a workaround for these peptides; it is how they were studied. That is a useful anchor when providers ask whether an oral format can carry a peptide at all.

For a peptide like GHK-Cu, the oral dissolving strip is about the delivery route rather than the molecule. Sublingual and buccal absorption through the oral mucosa bypasses the digestive degradation that makes a swallowed peptide capsule largely ineffective, and it adds systemic exposure that a topical serum alone does not provide. We walk through the mechanics of that route in the oral mucosa as a delivery route and compare it with injection in sublingual versus injectable bioavailability. The practical takeaway for aesthetics is that topical and systemic delivery are complementary: a topical signal peptide acts where it is applied, while an oral strip supports the tissue from the inside.

The Compliance Frame for Aesthetic Peptides

Aesthetic peptides live mostly in cosmetic territory, and cosmetic territory has its own claims line. A cosmetic product may address the appearance of skin; it may not claim to treat, cure, or prevent a condition without becoming, in the eyes of a regulator, an unapproved drug. The Federal Trade Commission also holds health-related advertising to a competent-and-reliable-scientific-evidence standard, which for many of these peptides means the modest, appearance-focused language the studies support and nothing beyond it. None of the peptides discussed here is an FDA-approved treatment, and a program should never imply that they are. Our guide on talking to patients about peptides without overclaiming works through the exact phrasing that keeps aesthetic peptide conversations on the right side of that line, and the same restraint applies to every one of these families.

The Bottom Line for Practices

The aesthetic peptide category rewards a provider who can tell its three families apart. Signal peptides message fibroblasts topically. Neuromodulating peptides soften expression lines topically. Collagen peptides supply building blocks systemically and carry the strongest human trial evidence of the group. GHK-Cu remains the defensible entry point because its research is deep and its mechanism is broad, and the rest of the landscape is where a practice grows from there. Hold every claim to what the studies actually measured, describe appearance rather than promise transformation, and the peptide line becomes an asset that a regulation-sensitive patient base can trust.

The aesthetic strip in our wholesale program is GHK-Cu, delivered through patented InstaRelease® technology by InstaMed, and our team can walk you through the product documentation before you decide where peptides fit in your practice. Apply for a free wholesale account.

References

1. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. PubMed: 29986520
2. Robinson LR, Fitzgerald NC, Doughty DG, Dawes NC, Berge CA, Bissett DL. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci. 2005;27(3):155-160. PubMed: 18492182
3. Blanes-Mira C, Clemente J, Jodas G, et al. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002;24(5):303-310. PubMed: 18498523
4. Proksch E, Segger D, Degwert J, Schunck M, Zague V, Oesser S. Oral supplementation of specific collagen peptides has beneficial effects on human skin physiology: a double-blind, placebo-controlled study. Skin Pharmacol Physiol. 2014;27(1):47-55. PubMed: 23949208
5. Bolke L, Schlippe G, Gerß J, Voss W. A Collagen Supplement Improves Skin Hydration, Elasticity, Roughness, and Density: Results of a Randomized, Placebo-Controlled, Blind Study. Nutrients. 2019;11(10):2494. PubMed: 31627309
6. de Miranda RB, Weimer P, Rossi RC. Effects of hydrolyzed collagen supplementation on skin aging: a systematic review and meta-analysis. Int J Dermatol. 2021;60(12):1449-1461. PubMed: 33742704

Disclaimer: This article is for educational purposes for healthcare providers and is not medical advice. Statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease, and they are not FDA-approved. Much of the aesthetic peptide research is small, cosmetic in scope, or preclinical; individual results vary, and no outcome is guaranteed. Providers are responsible for evaluating clinical use within their own scope of practice and applicable laws.